|
|
|
| Observation of the Therapeutic Effects of Inhaled N-acetylcysteine Combined with Ustekinumab in the Treatment of Severe Pneumonia |
| HOU Fujian, WEI Zhaohui, ZHAO Yuewei |
| Department of Respiratory Medicine,Dingzhou People's Hospital,Dingzhou Hebei 073000 |
|
|
|
|
Abstract 【Objective】To investigate the curative effect of inhaled acetylcysteine combined with ulinastatin in the treatment of severe pneumonia.【Methods】A total of 110 patients with severe pneumonia admitted to our hospital from March 2021 to March 2023 were randomly divided into control group(receiving inhaled acetylcysteine combined with anti-infection treatment) and the observation group(receiving combined ulinastatin treatment on the basis of control group) with a ratio of 1∶1(55 cases in each group).All patients were treated for 2 weeks. The clinical efficacy, the time of fever reduction, the time of lung rales and cough disappearance, and the incidence of adverse reactions were compared between the two groups. Serum inflammatory factors [interleukin-6(IL-6), tumor necrosis factor-α(TNF-α), C-reactive protein(CRP)], blood gas analysis indicators [PaO2, SaO2 and PaCO2], acute physiology and chronic health status score System Ⅱ(APACHEⅡ) score were compared as well.【Results】The total effective rate of the observation group was 90.91%, which was significantly higher than 76.36% of the control group, and the difference was statistically significant(P<0.05). The time of fever reduction and disappearance of lung rales and cough in the observation group were significantly shorter than those in the control group(P<0.05). After 2 weeks of treatment, the levels of IL-6, TNF-α, CRP and PaCO2 in observation group were lower than those in control group(P<0.05), while PaO2 and SaO2 were significantly higher than those in control group(P<0.05). After 2 weeks of treatment, the physiological scores and chronic health status scores of the observation group were significantly lower than those of the control group, with statistical significance(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).【Conclusion】Inhaled acetylcysteine combined with ulinastatin is effective in the treatment of patients with severe pneumonia, which can effectively improve respiratory function and reduce inflammation without increasing the incidence of adverse reactions.It is worthy of clinical application.
|
|
Received: 30 June 2023
|
|
|
|
|
|
[1] 郑温馨,罗苑苑,李乐,等. 成人重症肺炎证治规律的数据挖掘与分析[J].广州中医药大学学报,2023,40(1):247-253.
[2] 张陈光,陈旭岩,张向阳,等. 营养风险筛查与老年重症肺炎预后的相关性[J].中国急救医学,2023,43(3):175-179.
[3] 王建伟,张庆龙,王楠楠,等. 重症肺炎患者治疗期间血清sICAM-1、IL-8动态监测对病情进展的影响[J].广东医学,2023,44(1):13-18.
[4] 中国医师协会急诊医师分会. 中国急诊重症肺炎临床实践专家共识[J].中国急救医学,2016,36(2):97-107.
[5] 陈云峰. 关于“中国成人社区获得性肺炎诊断和治疗指南(2016年版)”中重症肺炎诊断标准的商榷[J].中华结核和呼吸杂志,2017,40(8):639.
[6] 李涛,宋超,王妍. 血清presepsin、Ghrelin及APACHEⅡ评分评估老年重症肺炎患者预后的价值研究[J].国际检验医学杂志,2022,43(8):940-944.
[7] 罗松平,刘单霞,韦兆吉,等. 重症肺炎行有创机械通气患者ICU死亡的多因素分析及风险模型建立[J].中国急救医学,2023,43(4):268-272.
[8] 刘胜,范承武. CT诊断重症肺炎支原体肺炎的价值[J].中国医学物理学杂志,2021,38(7):842-845.
[9] 张康,姬文帅,孔欣欣,等. 序贯性脏器功能衰竭评分和CURB-65评分及肺炎严重指数评分对重症肺炎患者28天死亡的预测效能比较研究[J].中国全科医学,2023,26(18):2217-2222.
[10] 徐梦,卢瑞萍,朱丽,等. 外周血单核细胞中NLRP3 mRNA、Caspase-1 mRNA、IL-1β及IL-18表达水平与重症肺炎患者病情严重程度及预后的相关性分析[J].标记免疫分析与临床,2021,28(7):1110-1114.
[11] 肖太平,周欣,尤惠芳. 乙酰半胱氨酸雾化吸入辅助治疗对病毒性肺炎患者血清炎性因子及T淋巴细胞亚群水平的影响[J].中国药业,2023,32(1):83-86.
[12] 郝旭仲,徐翠萍,赵锦彤,等. 乌司他丁对肺炎克雷伯菌致重症肺炎大鼠的保护作用研究[J].中国临床药理学杂志,2022,38(19):2278-2281.
[13] 陈建东,黄立,陈凯,等. 莫西沙星注射液联合吸入性乙酰半胱氨酸治疗重症肺炎患者的临床研究[J].中国临床药理学杂志,2023,39(7):920-923.
[14] 龙宇,董敏,刘礼银,等. 乙酰半胱氨酸雾化吸入联合免疫球蛋白治疗老年肺炎疗效及对炎症因子的影响[J].中南医学科学杂志,2022,50(2):265-267.
[15] 牛侠,陈秀梅,郑艳会. 吸入性乙酰半胱氨酸肺泡灌洗对重症肺炎患者治疗效果观察[J].首都医科大学学报,2021,42(6):950.
[16] 谢辉,冯俊,黄秋杰,等. 乌司他丁联合参麦注射液治疗对重症肺炎患者心肌损伤保护及肺功能的影响[J].实用医学杂志,2022,38(10):1260-1264.
[17] 冯献荣,吴楠,牛微微. 乌司他丁联合注射用亚胺培南西司他丁钠治疗重症肺炎伴呼吸衰竭的临床效果[J].中国医药导报,2020,17(3):123-126.
[18] 蒋小芝,张辉,齐静文. 乙酰半胱氨酸雾化吸入联合乌司他丁用于ARDS机械通气患者的价值研究[J].临床医学工程,2022,29(10):1381-1382. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(6): 910-912. |
|
|
|
|
2024, Vol. 41 
